↓ Skip to main content

Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis

Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
10 tweeters

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis
Published in
Journal for Immunotherapy of Cancer, March 2017
DOI 10.1186/s40425-017-0226-5
Pubmed ID
Authors

Marc-Elie Nader, Jeffrey N. Myers, Paul W. Gidley

Abstract

Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent article reported a case of sudden bilateral hearing loss that occurred in a patient with metastatic melanoma being treated with pembrolizumab. The authors attributed that complication to an autoimmune reaction secondary to the treatment. This commentary discusses the importance of considering the diagnosis of leptomeningeal metastasis in patients with metastatic melanoma who present with new cranial nerve deficits.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 25%
Professor 1 13%
Professor > Associate Professor 1 13%
Student > Master 1 13%
Unknown 3 38%
Readers by discipline Count As %
Medicine and Dentistry 3 38%
Neuroscience 1 13%
Biochemistry, Genetics and Molecular Biology 1 13%
Unknown 3 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2017.
All research outputs
#1,891,604
of 9,689,121 outputs
Outputs from Journal for Immunotherapy of Cancer
#156
of 436 outputs
Outputs of similar age
#69,572
of 260,932 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#18
of 32 outputs
Altmetric has tracked 9,689,121 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 436 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,932 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.